Acute myeloid leukemia (AML) is the most common form of acute leukemia. Unfortunately, the prognosis is poor, mostly due to high frequency of relapses using the current treatment strategies. Over the last years, it has become increasingly evident that the response to AML treatment, measurable residual disease (MRD), is a very strong prognostic factor. However, problems with standardization and applicability in individual patients hamper clinical usage of MRD analyses.
Our research focuses on improvement and usage of analyses of measurable residual disease (MRD). We have recently developed a novel analysis using next generation sequencing for MRD in AML based on the presence of leukemia-specific mutations. We currently evaluate the clinical usability of this new technique called deep sequencing. We are also working with evaluation and improvement of the more established methods for MRD analysis; flow cytometry and RT-qPCR.
Our work is closely linked to the hematology diagnostics departments at Sahlgrenska University Hospital. The overall aim of our research is to improve the basis for treatment decisions for children and adults with acute leukemia. Due to an in increased treatment arsenal, we also work on early detection relapse in AML. We collaborate closely with clinical hematologists and pediatric oncologists and take active part in the Nordic Organization for Pediatric Hematology and Oncology and the Swedish AML group. For technical implementation of new techniques, we work closely with groups at Chalmers University of Technology. Together with our neighboring groups Lars Palmqvist, Julia Asp and Meena Kanduri, we form the Leukemia Research Laboratory, aiming for a fruitful hematological research environment and continuous translation of research results into clinical diagnostics.